Abstract
From March 1992 to August 1994 62 patients received high dose therapy either as intensification fur high risk breast cancer (31) or metastatic disease (31). Combination chemotherapy employed was: Cyclophosphamide (1.5g/m<sup>2</sup>×4 days), carboplatin (200mg/m<sup>2</sup>×4 days continuous infusion) and thiotepa (125mg/m<sup>2</sup>/4 days, continuous infusion). Conventional bone marrow harvested was used as a source of hemopoietic support in 37 patients. In all cases subcutaneous G-CSF was administered from day + 1 until neutrophil engraftment at a dose of 5 microg/k/day. In the rest 25 patients G-CSF mobilized peripheral blood stem cells were infused after high-dose therapy. Eleven out of 25 received G-CSF after the transplant in the same schedule than bone marrow transplant patients. The aim of this study was to analyze if there were difference in terms of engraftment, days of hospitalization, and requirements of transfusion between this groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
